Denali Therapeutics DNLI reported its Q4 earnings results on Tuesday, February 27, 2024 at 08:05 AM.
Here's what investors need to know about the announcement.
Earnings
Denali Therapeutics missed estimated earnings by -7.000000000000001%, reporting an EPS of $-0.86 versus an estimate of $-0.8.
Revenue was down $10.28 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.1 which was followed by a 5.0% drop in the share price the next day.
Here's a look at Denali Therapeutics's past performance:
Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
---|---|---|---|---|
EPS Estimate | -0.82 | -0.68 | -0.7 | -0.79 |
EPS Actual | -0.72 | 1.30 | -0.8 | -0.75 |
Revenue Estimate | 10.80M | 13.46M | 28.72M | 13.12M |
Revenue Actual | 1.27M | 294.12M | 35.14M | 10.28M |
** Listen to the earnings announcement yourself by clicking here. **
To track all earnings releases for Denali Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.